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The safest duration of anticoagulation after idiopathic deep vein thrombosis (DVT) is unknown. We conducted
a prospective study to assess the optimal duration of vitamin K antagonist (VKA) therapy considering the risk
of recurrence of thrombosis according to residual vein thrombosis (RVT). Patients with a ﬁrst unprovoked DVT
were evaluated for the presence of RVT after 3 months of VKA administration; those without RVT suspended
VKA, while those with RVT continued oral anticoagulation for up to 2 years. Recurrent thrombosis and/or
bleeding events were recorded during treatment (RVT group) and 1 year after VKA withdrawal (both groups).
Among 409 patients evaluated for unprovoked DVT, 33.2% (136 of 409 patients) did not have RVT and VKA was
stopped. The remaining 273 (66.8%) patients with RVT received anticoagulants for an additional 21 months;
during this period of treatment, recurrent venous thromboembolism and major bleeding occurred in 4.7% and
1.1% of patients, respectively. After VKA suspension, the rates of recurrent thrombotic events were 1.4% and
10.4% in the no-RVT and RVT groups, respectively (relative risk 5 7.4; 95% conﬁdence interval 5 4.9–9.9).
These results indicate that in patients without RVT, a short period of treatment with a VKA is sufﬁcient; in
those with persistent RVT, treatment extended to 2 years substantially reduces, but does not eliminate, the risk
of recurrent thrombosis. Am. J. Hematol. 86:914–917, 2011. VC 2011 Wiley-Liss, Inc.
Introduction
Long-term anticoagulant treatment is highly effective in
preventing recurrent venous thromboembolism (VTE) in
patients with idiopathic deep vein thrombosis (DVT) of the
lower limbs [1–3] but is associated with an increased risk
for major bleeding that may offset the beneﬁts of anticoagu-
lation [4]. Since the risk of recurrent VTE is believed to
gradually diminish over time, many patients with idiopathic
DVT may not require prolonged treatment with a vitamin K
antagonist (VKA) [5,6]. According to recent guidelines,
patients with unprovoked DVT should be treated for at least
3 months and should then be evaluated for the risks and
beneﬁts of long-term therapy [1]; however, identiﬁcation of
these patients is not always straightforward.
In recent years, several markers for the assessment of the
individual risk for recurrent thrombosis have been proposed.
Among these, D-dimer (D-d) assay and residual vein throm-
bosis (RVT), detected by compression ultrasonography (C-
US), have shown to be the most suitable methods for
assessing the optimal duration of VKA administration. In fact,
a number of studies have shown that negative results with
these parameters after 3–6 months of therapy can identify a
group of patients at low-risk for recurrent thrombosis in whom
VKA treatment can be stopped [7–10]. However, these previ-
ous investigations have some limitations; ﬁrst, in some trials,
30% of the patient population had provoked DVT [8,9]. In
addition, no clear indications were given for how long patients
with persistent RVT or positive D-dimer should be treated,
since a signiﬁcant risk for recurrent VTE persists even after 1
year of anticoagulation [7–9]. In fact, none of these studies
has offered clear results regarding assessment of the optimal
duration of VKA treatment, even after the analysis of pooled
data [11,12].
To overcome some of these shortcomings, the current inves-
tigation enrolled patients with a ﬁrst episode of unprovoked
DVT and managed patients based on ultrasonography-
detected RVT ﬁndings after 3 months of oral anticoagulant
therapy.
Patients and Methods
Patients with a ﬁrst episode of unprovoked proximal DVTwere eligible for
the study; informed consent for participation was given at the index DVTepi-
sode. Unprovoked DVT was deﬁned as a thrombotic episode in apparently
healthy individuals without evident risk factors, such as surgery, trauma,
immobilization, or acute medical illness in the previous 4 weeks. Patients with
active cancer, limited life expectancy, antiphospholipid antibody syndrome,
known thrombophilic states (deﬁciencies of antithrombin, protein C and S,
homozygosity for the FV Leiden or F II G20210A mutations or combined het-
erozygosity for the same), severe liver disease, renal failure and, ﬁnally, those
who lived too far from the recruiting center were excluded from the study.
This extended duration of anticoagulation based on compression ultrasonog-
raphy (DACUS) study was approved by the Institutional Review Boards of
participating centers (Palermo, Perugia, L’Aquila). All patients provided written
informed consent obtained in accordance with the Declaration of Helsinki.
Study design. This multicenter prospective study was conducted in
patients with a ﬁrst episode of symptomatic proximal DVT (index DVT)
detected by compression ultrasonography (C-US). Participants underwent
clinical examination to assess baseline conditions and exclude contraindi-
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cations. All patients received oral anticoagulants for 3 months [warfarin
(Coumadin1, Bristol-Myers Squibb) or acenocoumarol (Sintrom1, Novartis
Pharma)]; at this time, patients underwent C-US assessment for detection
of RVT. C-US of the affected leg was performed, and images were
obtained in transverse sections only. Lumen compressibility was evaluated
by gentle pressure of the probe; RVT diameter was taken by measuring
the distance between the anterior and posterior walls of the vein, on
freeze-frame B-mode images, during compression with the ultrasound
probe. The examination was performed with the patient in the supine posi-
tion with the leg externally rotated and slightly ﬂexed at the knee. Measure-
ments were taken at the common femoral vein, 1 cm below the inguinal
ligament and at popliteal vein, at the most prominent crease in the midpo-
pliteal fossa. RVT was calculated as follows: RVT 5 vein diameter during
compression (diameter b) 3 100/vein diameter before compression (diam-
eter a) (Fig. 1). RVT was arbitrarily scored as ‘‘absent’’ when 40% of vein
diameter. Patients were considered to have RVT when a persistent throm-
bus was present in at least one of the two vein segments examined. C-US
of the affected leg was performed, and images were obtained in transverse
sections only. The result of this assessment demonstrated fairly good cor-
relation (j 5 0.7403, 95% conﬁdence interval (CI) 5 0.70–0.86) [8].
Patients without RVT (no-RVT) suspended VKA therapy at 3 months
after diagnosis. Those with RVT (RVT group) continued VKA (Interna-
tional Normalized Ratio (INR) 5 2.0–3.0) for an additional 21 months; all
patients were evaluated at 1 year after discontinuation of VKA (Fig. 2).
Study outcomes and follow-up. Study outcomes were recurrent
proximal VTE (rVTE) and major bleeding detected during VKA therapy,
and rVTE detected during one-year of follow-up after VKA suspension
(post-RVT detection period (Fig. 2). Therefore, the post-RVT detection
period lasted 12 months in the no-RVT group and 33 months (21 while
on VKA and 12 of follow-up) in the RVT group. Comparison among
groups for rate of rVTE and death was analyzed considering only the
one-year follow-up after VKA suspension. Patients were instructed to
contact the clinical center and were trained to recognize symptoms
suggestive of VTE or bleeding. In cases of recurrence, the results of C-
US were compared with those of the previous examination; ultrasonog-
raphy was performed by investigators unaware of RVT status at study
entry. Diagnosis of recurrent proximal DVT was based on C-US ﬁndings
only; recurrent events were conﬁrmed if a previously fully compressible
segment (contralateral or ipsilateral) was no longer compressible or if
an increase of 4 mm or more in the diameter of the residual thrombus
during compression was detected [13]; in unclear cases, repetition of
the test (after 5–7 days) or contrast venography was performed. In
patients with suspected pulmonary embolism, diagnosis of rVTE was
based on objective algorithms, accordingly to the protocol of the center
[14]. Major bleeding was deﬁned as a decrease in hemoglobin of 2.0 g/
dL or more, intracranial or retroperitoneal bleeding, or bleeding needing
surgical intervention or blood transfusion. Minor bleedings comprised
all other bleeding events. To avoid potential bias in the evaluation of
suspected rVTE-standardized diagnostic algorithms were used [13,14].
All events were evaluated by the adjudication panel that was unaware
of patients’ treatment, center, and RVT status.
Statistics and ethics. Baseline differences between groups were
assessed by the v2 test (Yates’ correction) for categorical variables and
ANOVA test or Kruskal–Wallis test for parametric and nonparametric anal-
yses, as appropriate. Relative risks (RRs) and 95% CIs were also eval-
uated. Data were analyzed using Epi Info software (version 6.0, Centers
for Disease Control and Prevention, Atlanta, GA) and SPSS Software
(version 14.0, SPSS, Chicago, IL). All P values were two-sided, and P val-
ues less than 0.05 were considered statistically signiﬁcant.
Results
Patients and treatment groups
Of the 670 patients with unprovoked DVT diagnosed over
a period of 8 years (until October 2007), 166 patients were
excluded because they were enrolled in the DACUS study,
15 did not agree to participate, 58 had exclusion criteria,
and 22 experienced recurrent events in the period between
index DVT and the 3-month C-US. Thus, a total of 409
patients were included in the study. Baseline characteristics
are reported in Table I. Mean patient age was lower in the
no-RVT group; the presence of nonextensive DVT (involve-
Figure 1. Evaluation of residual vein thrombosis. RVT calculation 5 vein diame-
ter during compression (diameter b) 3 100/vein diameter before compression (di-
ameter a). RVT, residual vein thrombosis.
Figure 2. Study design. RVT Group indicates patients with RVTwho continued VKA for 24 months after the index DVT; No-RVT Group indicates patients without RVTwho
stopped VKA after 3 months from the index DVT. DVT, deep vein thrombosis; RVT, residual vein thrombosis; C-US, compression ultra-sonography; VKA, vitamin K antagonist.
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ment of one venous segment only) was detected in about
30% in both groups.
Assessment of RVT after 3 months of VKA showed the
absence of residual vein thrombi in 136 (33.2%) patients
(no-RVT group) and the presence of residual thrombi in the
remaining 273 patients (66.8%; RVT-group).
Outcomes
Because of the study design, outcomes occurring during
VKA therapy after RVT detection were analyzed in the RVT
group only. rVTE occurred in 13 of 273 patients (4.7%),
while major bleeding was seen in three of 273 cases
(1.1%; Table II).
Considering the one-year follow-up period after suspension
of anticoagulants, analysis of outcomes was performed in both
groups. rVTE and the number per 100 persons/year are
reported in Table II. The analysis was performed after exclud-
ing, in the RVT group, the patients who developed rVTE during
VKA therapy (n 5 13) and those lost to follow-up (n 5 2); in
total, 258 patients in the RVT group were analyzed. Recur-
rences occurred in more than 10% of patients in the RVT group
compared with less than 2% in the no-RVT group, with a RR of
rVTE of 7.4 (95% CI 5 4.9–9.9), between patients treated for
an additional 21 months (RVT group) versus the no-RVT
group. Among patients with RVT, more than 20% had recurrent
DVT in the contralateral leg, whereas concomitant DVTand PE
occurred in 25% of cases. In the no-RVT group, all the two
events occurred in the same leg of the index DVTwithout suspi-
cion of pulmonary embolism (Table II).
We also analyzed differences in the rate of recurrent
events considering sex and age. Older age and male sex
conferred a higher risk for rVTE in the RVT and no-RVT
groups; especially in patients with RVT, the presence of
age 65 years was associated with a RR of 1.69 (95% CI
5 1.23–4.61) in comparison with younger patients. Regard-
ing sex, there was a nonsigniﬁcant trend for male patients
to have a higher risk of developing rVTE (RR 5 1.32, 95%
CI 5 0.02–2.62) when compared with females (Table III).
Seventeen deaths occurred during follow-up (14 in the
RVT and three in the no-RVT group): two deaths were due
to acute myocardial infarction, three deaths were due to
cerebral ischaemia (one in the no-RVT group), and the
other 12 deaths were due to cancer (two in the no-RVT
group) diagnosed during follow-up. No deaths due to throm-
botic recurrences or bleeding were recorded. Two patients
in the RVT group were lost to follow-up.
Discussion
Optimal duration of VKA treatment in patients with a ﬁrst epi-
sode of idiopathic DVT is still a matter of debate, and current
recommendations are often difﬁcult to implement [6,15].
Assessment of individual risk of recurrent thrombosis is impor-
tant as it simpliﬁes management strategies in patients with
VTE, which is especially relevant if tailored to speciﬁc groups
of patients with different risks of recurrence [16]. Recently, new
parameters for the assessment of the individual risk for recur-
rent thrombosis have been proposed, that is, RVTassessment
and the D-dimer assay. Both are characterized by advantages
and disadvantages; the D-dimer assay is easy to perform, but
not all kits have been validated for this purpose and there is no
comparison between the different methods and assays [17].
Moreover, D-dimer testing can yield false positive results in a
number of clinical situations (cancer, chronic diseases,
advanced age, inﬂammatory status, infections, etc.). RVT
assessment is an easy method, does not seem to be inﬂu-
enced by the aforementioned conditions, but requires some ex-
pertise and is, to a certain extent, a subjective technique. A
very important issue is the fact that these tools can identify
patients carrying a low risk for recurrent VTE; these patients, in
fact, may safely beneﬁt from a short course (3 months) of VKA
treatment [7–9]. Concerning RVT speciﬁcally, the absence of a
residual clot is associated with a negligible risk for recurrent
VTE; this may allow a short course of VKA in about one-third
of the entire DVT patient population.
However, the correlation between RVT and the risk of
recurrent DVT (after VKA suspension) is still unclear. Le
Gal et al. carried out a multicenter, multinational prospec-
tive cohort study in tertiary care centers. Patients with a
ﬁrst unprovoked major VTE were enrolled over a 4-year
period and completed a mean follow-up of 18-months. All
452 patients with DVT had baseline C-US at inclusion to
assess RVT before stopping VKA at 5–7 months. All epi-
sodes of suspected recurrent VTE were independently
adjudicated with reference to baseline imaging after VKA
suspension. It was found that 45 of 231 patients with
abnormal CUS (19.5%) had recurrent VTE during follow-up,
TABLE I. Baseline Patient Characteristics
RVT group
(n 5 273)
No-RVT
group (n 5 136) P value*
Female sex (%) 132 (48.3) 62 (45.5) 0.683
Age, mean 1 SD (years) 57.8 ± 13.9 54.5 ± 14.6 0.054**
One segment DVT, n (%)a 78 (28.5) 42 (30.8) 0.065
Prevalence of prothrombin mutationb 19/181 (10.4%) 9/89 (10.1%) n.s.
Prevalence of factor V Leidenb 68/194 (35%) 29/91 (31.8%) n.s.
* P value refers to v2 test unless speciﬁed.
**
ANOVA test.
a
This means involvement of popliteal or common femoral vein only.
b
In patients tested at the moment of diagnosis or during follow-up.
RVT, residual vein thrombosis.
TABLE II. Study Outcomes
Outcomes
RVT group
(n 5 273)
No-RVT
group (n 5 136) P value*
During VKA therapy after RVT detectiona
Recurrences, n [(%), 95%
Conﬁdence Intervals]
13 [(4.7), 1.5–7.9] – –
Major bleeding, n [(%), 95%
Conﬁdence Intervals]
3 [(1.1), 20.1–2.3] – –
1 year after VKA discontinuationb
n 5 258c n 5 136
Recurrences, n [(%), 95%
Conﬁdence Intervals]
27 [(10.4), 6.7–14.1] 2 [(1.4), 20.523.3] 0.0026
Recurrences, no. per
100 person-years
10.4 1.4 0.022d
Types of rVTE (%)
DVT only 16 (59.2) 2 (1.4)
DVT 1 PE 7 (25.9) 0
Isolated PE 4 (14.8) 0
Controlateral DVT n (%) 6 (22.2) 0
Death, n (%) 14 (5.4) 3 (2.2) 0.038
* P value refers to v2 test unless speciﬁed.
a
Accordingly to study design, considered for RVT group only.
b
Excluding 13 patients having recurrent DVT during treatment in RVT group.
c
Two patients were lost to follow-up.
d v2 test for the comparison of two proportions, expressed as percentage.
RVT, residual vein thrombosis; VKA, vitamin-K antagonist.
TABLE III. Recurrent Venous Thromboembolism in Subgroups After VKA
Discontinuation
Subgroups
RVT group (n 5 258) No-RVT group (n 5 136)
No. of
events/total (%)
No. per 100
person-years
No. of
events/total (%)
No. per 100
person-years
Sex
Male 15/131 (11.4) 11.4 2/72 (2.7) 2.7
Female 12/127 (9.4) 8.6 0/64 (0.0) 0.0
Age
<65 years 11/139 (7.9) 7.9 0/78 (0.0) 0.0
65 years 16/119 (13.4) 13.4 2/58 (3.4) 3.4
RVT, residual vein thrombosis; VKA, vitamin-K antagonist.
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compared with 32 of 220 patients with normal CUS
(14.6%). The association between abnormal CUS at inclu-
sion and risk of recurrent VTE yielded a hazard ratio that
was not signiﬁcant (1.4, 95% CI 5 0.9–2.1) [18]. These
data were not conﬁrmed by a recent systematic review
showing that residual thrombosis positively correlated with
recurrent VTE, although large heterogeneities were pres-
ent, due to differences in study population, timing, and dif-
ferences in methods of measuring residual thrombosis [12].
Other studies have evaluated whether detection of RVT may
establish the optimal duration of VKA therapy. Prandoni et al.
used residual thrombus assessed over time to drive anticoagu-
lant therapy [9]. Patients were randomly assigned to ﬁxed-dura-
tion anticoagulation (no further anticoagulation for secondary
thrombosis and an extra 3 months for unprovoked thrombosis)
or ﬂexible-duration, ultrasonography-guided anticoagulation
(no further anticoagulation in patients with recanalized veins
and continued anticoagulation in all other patients for up to 9
months for secondary DVT and up to 21 months for unpro-
voked thrombosis). It was found that 46 (17.2%) of 268 patients
allocated to ﬁxed-duration anticoagulation and 32 (11.9%) of
270 patients allocated to ﬂexible-duration anticoagulation
developed recurrent VTE [adjusted hazard ratio (HR) 5 0.64,
95% CI 5 0.39–0.99]. Considering patients with unprovoked
DVT, the adjusted HR was 0.61 (CI5 0.36–1.02).
In the DACUS study, we showed that among patients (n
5 180) with RVT after 3 months of VKA, recurrent events
occurred in 27.2% of those who discontinued (25 of 92
patients; 15.2% person-years) and 19.3% of those who
continued VKA (17 of 88 patients; 10.1% person-years) for
an additional 9 months. Of the 78 (30.2%) patients without
RVT, only one (1.3%; 0.63% person-years) experienced re-
currence. The adjusted HR of patients with RVT versus
those without was 24.9 (95% CI 5 3.4–183.6; P 5 0.002)
[8]. Considering all unprovoked DVT patients without RVT
(28 from the DACUS study and 136 in the current study),
the risk of rVTE after VKA suspensions is as low as 1.2%
(two of 164 patients, 95% CI 5 0.15–2.63). The situation is
quite different in high-risk patients identiﬁed by the pres-
ence of a residual vein clot after 3 months of VKA treat-
ment (RVT-group). In this population, in fact, the continua-
tion of VKA up to 1 year (9 months after RVT detection)
only delayed the incidence of recurrent events [8].
Considering the above, RVT-based management of patients
with unprovoked DVT still requires further study. Toward this
end, we investigated 409 patients with unprovoked DVT, man-
aged entirely accordingly to RVT detection after 3 months of
VKA. Detection of RVT at this time may be considered some-
what premature, although our approach reﬂects previous ﬁnd-
ings [8,12,19]. In this view, early RVT detection may be an
appropriate marker for assessing the minimal length of VKA in
low risk patients. In our study, we stopped VKA after 3 months
in patients without RVT, while those with RVT received longer
treatment schedules (additional 21 months after RVT detec-
tion); all patients underwent a 1-year follow-up visit after VKA
discontinuation. This approach reﬂects our current clinical prac-
tice and is also in accordance with the 8th ACCP guidelines
that suggest periodic revaluation of the risk-beneﬁt ratio of
long-term therapy. Results of the present investigation clearly
conﬁrm that in patients without RVT, the risk of recurrent throm-
bosis remains low even after 1 year of follow-up; in patients
with RVT, recurrent events still occur in up to 10% of cases
even if patients were treated for almost 2 years. In this group of
patients, no signiﬁcant differences were found compared with
those observed in the DACUS study where RVT patients were
treated for an additional 9 months instead of 21 months in pres-
ent investigation [8]. It is clear that the results of these two trials
are difﬁcult to compare because the DACUS study also
included patients with provoked DVT; however, these
results may suggest that there is an advantage of indeﬁnite
anticoagulation in high-risk patients. On the other hand, in
patients with RVT anticoagulation with VKA is unsatisfactory,
because it cannot completely eliminate the ‘‘predisposition’’ to
relapse, as suggested by the rate of recurrences observed dur-
ing anticoagulant therapy (4.7%). As we did not further evalu-
ate RVT during follow-up, it cannot be excluded that some of
these patients may reduce their RVT burden over time and,
thus, carry a different risk for relapsing [9]. Obviously, such
considerations need to be evaluated prospectively.
In conclusion, this study indicates that in patients with idi-
opathic DVT, the absence of RVT is associated with a low
risk for recurrence and safely permits discontinuation of
VKA after 3 months.
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